HighTower Advisors LLC Increases Stock Holdings in Neuronetics, Inc. (NASDAQ:STIM)

HighTower Advisors LLC raised its stake in shares of Neuronetics, Inc. (NASDAQ:STIM) by 55.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 245,982 shares of the company’s stock after purchasing an additional 87,816 shares during the period. HighTower Advisors LLC owned 0.81% of Neuronetics worth $187,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Gabelli Funds LLC raised its stake in Neuronetics by 88.2% in the 2nd quarter. Gabelli Funds LLC now owns 48,000 shares of the company’s stock valued at $86,000 after purchasing an additional 22,500 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Neuronetics in the 3rd quarter valued at $53,000. GSA Capital Partners LLP lifted its position in Neuronetics by 64.5% in the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after buying an additional 30,837 shares during the last quarter. Dorsey & Whitney Trust CO LLC boosted its position in shares of Neuronetics by 97.1% during the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 95,880 shares of the company’s stock worth $173,000 after purchasing an additional 47,228 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Neuronetics by 124.5% during the second quarter. Renaissance Technologies LLC now owns 322,200 shares of the company’s stock worth $580,000 after buying an additional 178,700 shares during the period. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Neuronetics Stock Performance

NASDAQ STIM opened at $1.46 on Thursday. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The company has a market cap of $44.31 million, a P/E ratio of -1.19 and a beta of 2.26. The stock has a 50-day moving average of $1.06 and a two-hundred day moving average of $1.24. Neuronetics, Inc. has a 1-year low of $0.52 and a 1-year high of $5.07.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.